Edition:
United States

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

0.93USD
22 Oct 2018
Change (% chg)

-- (--)
Prev Close
$0.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
543,066
52-wk High
$3.58
52-wk Low
$0.76

Chart for

About

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in... (more)

Overall

Beta: -0.58
Market Cap(Mil.): $226.73
Shares Outstanding(Mil.): 76.08
Dividend: --
Yield (%): --

Financials

  TRVN.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -0.78 -- --
ROI: -74.16 1.96 12.83
ROE: -104.01 1.12 14.95

UPDATE 2-Trevena's opioid painkiller fails to get FDA panel backing

Oct 11 Trevena Inc's opioid injection for managing acute pain failed to win the backing of an advisory panel to the Food and Drug Administration on Thursday, against the backdrop of opioid addiction in the United States reaching epidemic proportion.

Oct 11 2018

Trevena's opioid painkiller fails to get FDA panel nod

Oct 11 An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approval of Trevena Inc's opioid injection for managing acute pain.

Oct 11 2018

FDA staff raises safety issues over Trevena opioid injection

Trevena Inc's opioid injection to treat acute pain could be abused and potentially lead to overdose, staff reviewers of the U.S. Food and Drug Administration said on Tuesday, sending the drugmaker's shares down 66 percent.

Oct 09 2018

UPDATE 1-FDA staff raises safety issues over Trevena opioid injection

Oct 9 Trevena Inc's opioid injection to treat acute pain could be abused and potentially lead to overdose, staff reviewers of the U.S. Food and Drug Administration said on Tuesday, sending the drugmaker's shares down 66 percent.

Oct 09 2018

FDA staff raises safety concerns over Trevena opioid drug

Oct 9 Staff reviewers of the U.S. Food and Drug Administration on Tuesday raised safety concerns over Trevena Inc's opioid injection to treat acute pain, saying the treatment has an abuse and overdose potential.

Oct 09 2018

BRIEF-Trevena Appoints Mark Demitrack As Chief Medical Officer

* TREVENA APPOINTS MARK A. DEMITRACK, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

May 21 2018

BRIEF-Trevena Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S

May 03 2018

BRIEF-Trevena Inc And Jiangsu Nhwa Pharmaceutical Announce License Agreement For Oliceridine In China

* TREVENA INC. AND JIANGSU NHWA PHARMACEUTICAL CO. LTD ANNOUNCE LICENSE AGREEMENT FOR OLICERIDINE IN CHINA

May 01 2018

Earnings vs. Estimates